Tarazi F I
Consolidated Department of Psychiatry and Neuroscience Program, Harvard Medical School; Boston, MA; Mailman Research Center, McLean Division of Massachusetts General Hospital, Belmont, MA 02478, USA. E-mail:
J Sci Res Med Sci. 2001 Oct;3(2):93-104.
There has been an extraordinary recent accumulation of information concerning the neurobiology and neuropharmacology of dopamine (DA) receptors in the mammalian central nervous system. Many new DA molecular entities have been cloned, their gene, peptide sequences and structures have been identified, their anatomical distributions in the mammalian brain described, and their pharmacology characterized. Progress has been made toward developing selective ligands and drug-candidates for different DA receptors. The new discoveries have greatly stimulated preclinical and clinical studies to explore the neuropharmacology of DA receptors and their implications in the neuropathophysiology of different neuropsychiatric diseases including schizophrenia, Parkinson's disease and attention-deficit hyperactivity disorder. Accordingly, it seems timely to review the salient aspects of this specialized area of preclinical neuropharmacology and its relevance to clinical neuropsychiatry.
最近，有关哺乳动物中枢神经系统中多巴胺（DA）受体的神经生物学和神经药理学的信息大量积累。许多新的DA分子实体已被克隆，其基因、肽序列和结构已被确定，其在哺乳动物脑中的解剖分布已被描述，其药理学特性也已明确。在开发针对不同DA受体的选择性配体和候选药物方面已取得进展。这些新发现极大地推动了临床前和临床研究，以探索DA受体的神经药理学及其在包括精神分裂症、帕金森病和注意力缺陷多动障碍在内的不同神经精神疾病的神经病理生理学中的意义。因此，回顾这一临床前神经药理学专业领域的突出方面及其与临床神经精神病学的相关性似乎是适时的。
